Fig. 4.
Fig. 4. RES inhibition by antierythrocyte monoclonal antibodies. / (A) SCID mice were injected intravenously with 50 μg anti-CD24 (IgG2b, ⋄) or anti-CD24 (IgG2c, ○) or intraperitoneally with 50 mg IVIG (▵) or albumin (■) 24 hours prior to intravenous injection of 200 μL PKH26-labeled, TER-119 antibody–sensitized SCID mouse erythrocytes. Blood was sampled at the specified time points, and the percentage of fluorescent erythrocytes was assessed by flow cytometry. The percentage of fluorescent erythrocytes at the 3-minute time point was considered to be 100%. (B) SCID mice were injected with the indicated reagent and assessed as in panel A; n = 9 for each group. *P < .05; **P < .01; ***P < .001 as compared with albumin mice. Error bars indicate SEM.

RES inhibition by antierythrocyte monoclonal antibodies.

(A) SCID mice were injected intravenously with 50 μg anti-CD24 (IgG2b, ⋄) or anti-CD24 (IgG2c, ○) or intraperitoneally with 50 mg IVIG (▵) or albumin (■) 24 hours prior to intravenous injection of 200 μL PKH26-labeled, TER-119 antibody–sensitized SCID mouse erythrocytes. Blood was sampled at the specified time points, and the percentage of fluorescent erythrocytes was assessed by flow cytometry. The percentage of fluorescent erythrocytes at the 3-minute time point was considered to be 100%. (B) SCID mice were injected with the indicated reagent and assessed as in panel A; n = 9 for each group. *P < .05; **P < .01; ***P < .001 as compared with albumin mice. Error bars indicate SEM.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal